JP Stock MarketDetailed Quotes

4565 Nxera Pharma

Watchlist
  • 1053
  • +31+3.03%
20min DelayMarket Closed Dec 27 15:30 JST
94.67BMarket Cap-12.08P/E (Static)

Nxera Pharma Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Nxera Pharma Q3 2024 Earnings Date

Currency：JPYNov 1, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
16.60B
9.26B
-7.34B
Miss Est.
+398.80%
+178.34%
-44.20%
EPS
-6.33
13.45
+19.78
Beat Est.
+89.44%
+122.49%
+312.60%
Analyst Rating
Strong Buy

Dec 11, 2024

Nxera Pharma Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: JPY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 12.906B--
Nov 1, 20242024/Q39.263B / 16.600B--
Aug 9, 20242024/Q28.109B / 8.500B--
May 9, 20242024/Q14.611B / 11.300B--
Feb 13, 20242023/Q47.292B / 13.254B--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 12.906B--
Nov 1, 20242024/Q39.263B / 16.600B--
Aug 9, 20242024/Q28.109B / 8.500B--
May 9, 20242024/Q14.611B / 11.300B--
Feb 13, 20242023/Q47.292B / 13.254B--

Unlock Free Earnings Estimates

Nxera Pharma Earnings Reports

  • Nxera Pharma: Business highlights and consolidated financial results for the 3rd quarter (January-September) of the fiscal year ending 2024/12

    Nov 1 02:30 ET

  • Nxera Pharma: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [IFRS] (consolidated)

    Nov 1 02:30 ET

  • Nxera Pharma: Confirmatory letter.

    Aug 9 03:02 ET

  • Nxera Pharma: Interim report - 35th period (01/01/2024 - 12/31/2024)

    Aug 9 03:01 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Dec 11, 2024

    Strong Buy

    • Strong Buy

      70.00%

    • Buy

      20.00%

    • Hold

      10.00%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    JP
    Overall
    Symbol
    Price
    % Chg

    No Data